Seco-Duocarmycin SA is a potent ADC cytotoxin payload with alkylating activity that selectively targets DNA in tumor cells. It enhances antibody-drug conjugate efficacy through precise cytotoxic payload delivery, aiding in targeted cancer therapies with improved safety profiles.
Structure of 152785-82-5
* For research and manufacturing use only. We do not sell to patients.
Size | Price | Stock | Quantity |
---|---|---|---|
5 mg | $1574 | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Seco-Duocarmycin SA is a highly potent DNA-alkylating agent and a promising ADC cytotoxin used as an ADC payload in antibody-drug conjugates. This compound binds selectively to the minor groove of DNA, inducing sequence-specific alkylation and causing irreversible DNA damage. Its extreme cytotoxicity makes it ideal for targeted cancer therapies, particularly when integrated into ADC platforms for selective tumor delivery.
Within antibody-drug conjugates, Seco-Duocarmycin SA is typically linked to monoclonal antibodies via cleavable linkers, enabling controlled release inside tumor cells. Once internalized, the payload is liberated by enzymatic cleavage, allowing it to interact with DNA and trigger apoptosis. This tumor-specific mechanism ensures maximal cytotoxic activity at the cancer site while minimizing off-target toxicity, making Seco-Duocarmycin SA a highly effective payload option in oncology-focused ADC design.
Applications of Seco-Duocarmycin SA include its incorporation into experimental ADCs targeting both hematologic malignancies and solid tumors, such as breast cancer, lung cancer, and ovarian cancer. Its high potency allows effective therapeutic effects even at low drug-to-antibody ratios (DARs). Researchers also leverage its structural compatibility with diverse linker technologies to optimize conjugation efficiency, payload stability, and intracellular release, facilitating the development of next-generation antibody-drug conjugates with improved selectivity and antitumor efficacy.
Catalog | Product Name | CAS | Inquiry |
---|---|---|---|
BADC-00811 | Duocarmycin DM free base | 1116745-06-2 | |
BADC-00337 | Seco-Duocarmycin TM | 1142188-60-0 | |
BADC-00223 | Duocarmycin A | 118292-34-5 | |
BADC-00362 | Duocarmycin B1 | 124325-93-5 | |
BADC-00605 | Duocarmycin TM | 157922-77-5 | |
BADC-00332 | Seco-DuocarmycinCN | 1613286-54-6 | |
BADC-00333 | Seco-DuocarmycinDMG | 1613286-55-7 | |
BADC-00342 | Seco-Duocarmycin MA | 1613286-57-9 | |
BADC-00609 | Duocarmycin MB | 1613286-58-0 | |
BADC-00336 | Seco-Duocamycin GA | 1613286-59-1 |
What is Seco-Duocarmycin SA?
Seco-Duocarmycin SA is a synthetic cytotoxic compound designed for use in ADCs. It binds to DNA minor grooves and alkylates nucleotides, leading to cell cycle arrest and apoptosis. Its chemical structure supports effective conjugation with antibody carriers.
22/4/2019
Dear team, how is Seco-Duocarmycin SA applied in ADCs?
In ADCs, Seco-Duocarmycin SA serves as the cytotoxic payload attached to a targeting antibody. It ensures selective delivery to cells expressing the target antigen, thereby limiting off-target cytotoxicity and enhancing therapeutic precision.
12/12/2018
Dear team, what linker strategies are suitable for Seco-Duocarmycin SA?
Seco-Duocarmycin SA can be attached using cleavable linkers that respond to intracellular conditions, enabling drug release within target cells, or non-cleavable linkers for improved circulation stability and controlled pharmacokinetics.
21/2/2019
Could you kindly share what precautions are needed when handling Seco-Duocarmycin SA?
Due to its high cytotoxic potential, Seco-Duocarmycin SA must be handled in controlled laboratory environments using protective equipment and containment systems. Following institutional and regulatory safety protocols is critical during synthesis and conjugation.
19/7/2022
Good morning! What benefits do Seco-Duocarmycin SA ADCs provide in research?
Seco-Duocarmycin SA ADCs allow for targeted cell killing while minimizing systemic exposure. This specificity improves the therapeutic index, facilitates preclinical studies, and supports development of safer, more effective oncology treatments.
20/9/2016
— Dr. James Parker, Lead Scientist (USA)
High-purity Seco-Duocarmycin SA from BOC Sciences enabled smooth ADC conjugation.
21/2/2019
— Dr. Olivia Harris, Research Scientist (UK)
Fast delivery and responsive support. Seco-Duocarmycin SA batch consistency was excellent.
20/9/2016
— Dr. Lars Fischer, Medicinal Chemist (Germany)
Technical team provided detailed documentation for Seco-Duocarmycin SA, aiding regulatory compliance.
19/7/2022
— Dr. Emily Carter, Biochemist (Canada)
Seco-Duocarmycin SA arrived on time and matched all analytical specifications.
22/4/2019
— Dr. William Hayes, Principal Investigator (USA)
Reliable supply and clear QC reports for Seco-Duocarmycin SA. Critical for our cytotoxicity assays.
— Dr. Sophie Dubois, ADC Scientist (France)
Consistent quality and excellent support. Highly recommend BOC Sciences for Seco-Duocarmycin SA.
12/12/2018
Contact our experts today for pricing and comprehensive details on our ADC offerings.
From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.
Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.
Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.